Johnson & Johnson announced a $2.5 billion dollar settlement agreement for patients who had a DePuy ASR hip implanted and then revised before August 31, 2013. J&J will pay $250,000 to qualified patients who had their ASR metal on metal hip implants removed and replaced with another type of hip device. However, that amount can be reduced based on other factors, such as a patient’s age, if they smoked, if they had a high Body Mass Index, and other medically related details. There is additional money available in the settlement for people who’ve suffered from “extraordinary injuries” related to their ASR implant, such as a double hip revision, stroke, heart attack, pulmonary embolism, deep vein thrombosis, and dislocations. In their official press release, Johnson & Johnson says, “the majority of the payments related to this settlement are projected to occur during 2014 from currently available cash.”
What Should Patients Do Next?
The deadline to register your settlement claim is January 6, 2014. Your attorney will contact you very soon with details about the entire claims process. Because the deadline for ALL claims is less than 2 months from now, there’s no time to wait before filing. Even if you haven’t filed a lawsuit, you are still eligible for the cash settlement as long as you qualify.
Who is Not Covered by the Settlement?
Anyone who has a revision surgery AFTER August 31 of this year is NOT eligible for the settlement and they must go through the existing Broadspire program, according to the J&J press release. Also, the agreement does not cover medical issues related to high levels of cobalt chromium debris in a patient’s bloodstream.
If you do not yet have an attorney to represent you in this settlement, Maglio Christopher & Toale, P.A. can help you file your DePuy ASR hip settlement claim. Contact us at 888-952-5242 or fill out the form on the right side of this page. We will get back in touch with you immediately with details about what you should do next since there is so little time to register your claim.